Literature DB >> 34174988

Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?

Clare Sun1, Adrian Wiestner2.   

Abstract

Reversing or preventing immunodeficiency in patients with chronic lymphocytic leukemia (CLL) is of the highest priority. The past decade of research has met the challenge of treating CLL for most patients. Patients continue to struggle, however, with infections and second primary malignancies related to immunodeficiency. Strategies addressing this need currently are limited to vaccinations, with suboptimal efficacy, and immunoglobulin replacement. Correlative studies have provided insights into immunologic alterations on treatment. Understanding vulnerabilities in the immune system may help identify potential interventions to boost immunity. An emphasis on systematically testing such interventions is required to restore immunocompetence in patients with CLL. Published by Elsevier Inc.

Entities:  

Keywords:  Hypogammaglobulinemia; Infection; Leukemia; Second primary malignancy; T cell; Vaccine

Mesh:

Year:  2021        PMID: 34174988      PMCID: PMC8269747          DOI: 10.1016/j.hoc.2021.03.010

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   2.861


  135 in total

1.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Authors:  M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

2.  Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.

Authors:  Michael C Schmid; Christie J Avraamides; Holly C Dippold; Irene Franco; Philippe Foubert; Lesley G Ellies; Lissette M Acevedo; Joan R E Manglicmot; Xiaodan Song; Wolfgang Wrasidlo; Sara L Blair; Mark H Ginsberg; David A Cheresh; Emilio Hirsch; Seth J Field; Judith A Varner
Journal:  Cancer Cell       Date:  2011-06-14       Impact factor: 31.743

3.  Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Authors:  Nitin Jain; Michael Keating; Philip Thompson; Alessandra Ferrajoli; Jan Burger; Gautam Borthakur; Koichi Takahashi; Zeev Estrov; Nathan Fowler; Tapan Kadia; Marina Konopleva; Yesid Alvarado; Musa Yilmaz; Courtney DiNardo; Prithviraj Bose; Maro Ohanian; Naveen Pemmaraju; Elias Jabbour; Koji Sasaki; Rashmi Kanagal-Shamanna; Keyur Patel; Jeffrey Jorgensen; Naveen Garg; Xuemei Wang; Katrina Sondermann; Nichole Cruz; Chongjuan Wei; Ana Ayala; William Plunkett; Hagop Kantarjian; Varsha Gandhi; William Wierda
Journal:  N Engl J Med       Date:  2019-05-30       Impact factor: 91.245

4.  Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma.

Authors:  A M Arvin; R B Pollard; L E Rasmussen; T C Merigan
Journal:  J Clin Invest       Date:  1980-04       Impact factor: 14.808

5.  The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.

Authors:  Julia Hoellenriegel; Sarah A Meadows; Mariela Sivina; William G Wierda; Hagop Kantarjian; Michael J Keating; Neill Giese; Susan O'Brien; Albert Yu; Langdon L Miller; Brian J Lannutti; Jan A Burger
Journal:  Blood       Date:  2011-07-29       Impact factor: 22.113

6.  Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.

Authors:  Clare Sun; Xin Tian; Yuh Shan Lee; Sreenivasulu Gunti; Andrew Lipsky; Sarah E M Herman; Dalia Salem; Maryalice Stetler-Stevenson; Constance Yuan; Lela Kardava; Susan Moir; Irina Maric; Janet Valdez; Susan Soto; Gerald E Marti; Mohammed Z Farooqui; Abner L Notkins; Adrian Wiestner; Georg Aue
Journal:  Blood       Date:  2015-09-03       Impact factor: 22.113

7.  A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction.

Authors:  Barbara P Yawn; Patricia Saddier; Peter C Wollan; Jennifer L St Sauver; Marge J Kurland; Lina S Sy
Journal:  Mayo Clin Proc       Date:  2007-11       Impact factor: 7.616

8.  Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.

Authors:  Iris de Weerdt; Tom Hofland; Renate de Boer; Johan A Dobber; Julie Dubois; Denise van Nieuwenhuize; Mehrdad Mobasher; Fransien de Boer; Mels Hoogendoorn; Gerjo A Velders; Marjolein van der Klift; Ester B M Remmerswaal; Frederike J Bemelman; Carsten U Niemann; Sabina Kersting; Mark-David Levin; Eric Eldering; Sanne H Tonino; Arnon P Kater
Journal:  Blood Adv       Date:  2019-09-10

9.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

Authors:  John C Riches; Jeffrey K Davies; Fabienne McClanahan; Rewas Fatah; Sameena Iqbal; Samir Agrawal; Alan G Ramsay; John G Gribben
Journal:  Blood       Date:  2012-12-17       Impact factor: 22.113

10.  Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia.

Authors:  Lindsey E Roeker; David A Knorr; Melissa S Pessin; Lakshmi V Ramanathan; Meghan C Thompson; Lori A Leslie; Andrew D Zelenetz; Anthony R Mato
Journal:  Leukemia       Date:  2020-08-27       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.